feed,title,long_url,short_url
BioRxiv,Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies,https://biorxiv.org/cgi/content/short/2022.01.29.478316v1?rss=1,https://bit.ly/3ITXVPW
BioRxiv,In silico analysis of predicted differential MHC binding and CD8+ T-cell immune escape of SARS-CoV-2 B.1.1.529 variant mutant epitopes,https://biorxiv.org/cgi/content/short/2022.01.31.478157v1?rss=1,https://bit.ly/3KWq8aJ
BioRxiv,How 1 concerning is a sars-cov-2 variant of2 concern? computational predictions and3 the variants labeling system,https://biorxiv.org/cgi/content/short/2022.01.31.478425v1?rss=1,https://bit.ly/3IQKwrP
BioRxiv,Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia,https://biorxiv.org/cgi/content/short/2022.01.25.477616v1?rss=1,https://bit.ly/3s4v6tm
BioRxiv,Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants,https://biorxiv.org/cgi/content/short/2022.01.31.478406v1?rss=1,https://bit.ly/3odTHdY
BioRxiv,Susceptibility of wild canids to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),https://biorxiv.org/cgi/content/short/2022.01.27.478082v1?rss=1,https://bit.ly/3KWq9eN
BioRxiv,Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodies,https://biorxiv.org/cgi/content/short/2022.01.30.478305v1?rss=1,https://bit.ly/347LYaL
BioRxiv,An intranasal lentiviral booster broadens immune recognition of SARS-CoV-2 variants and reinforces the waning mRNA vaccine-induced immunity that it targets to lung mucosa,https://biorxiv.org/cgi/content/short/2022.01.30.478159v1?rss=1,https://bit.ly/3ucE8qY
BioRxiv,SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection,https://biorxiv.org/cgi/content/short/2022.01.29.478335v1?rss=1,https://bit.ly/3KWq8HL
